Accurate laboratory wavelengths of the e 3 Σ–(ν' = 5) – X 1 Σ+(ν'' = 0) band of 12C16O

CITATION: Dickenson, G. D. et al. 2010. Accurate laboratory wavelengths of the e 3 Σ–(ν' = 5) – X 1 Σ+(ν'' = 0) band of 12C16O. Astrophysical Journal Letters, 714(2):L268–L270, doi:10.1088/2041-8205/714/2/L268.The original publication is available at https://iopscience.iop.org/journal/2041-8205The forbidden singlet-triplet transitions of carbon monoxide (CO) are important in the interpretation of vacuum ultraviolet interstellar absorption spectra and in particular for the measurement of large CO column densities. Twenty rovibronic lines of the e 3Σ–(ν' = 5) – X 1Σ+(ν'' = 0) band of 12 C 16O for which laboratory wavelengths were previously unavailable were identified in laser-induced fluorescence excitation spectra. Wavelengths were assigned to five rovibronic transitions to an average accuracy of 0.0028 Å. A further 15 lines could not be fully resolved and average wavelengths were measured for these groups of closely spaced lines. A wavelength difference of 0.011 ± 0.0028 Å between the measured wavelengths and the calculated wavelengths in the atlas of Eidelsberg & Rostas demonstrates the need for more experimental data on CO.https://iopscience.iop.org/article/10.1088/2041-8205/714/2/L268Publisher's versio

The Impact of Exercise and Nutrition Science Education on the Neuro-Agility of University Students

https://drive.google.com/file/d/15MJldSdzC-G6D3y3M4Y7YSmRNgOvxxRg/view?usp=sharinghttps://drive.google.com/drive/folders/15NiOAXE10ILUJLkTJzPgdB5U5aNk7Ph_?usp=sharinghttps://drive.google.com/drive/folders/1K3qrbFiYK_l1PypqIExld4n3QO8f8Ref?usp=sharin

Applying supervised machine learning to predict optimal playing positions for netball players

https://drive.google.com/file/d/1WbC-0ocZwv8JBj6QYjp4mGcknFw1fgOW/view?usp=sharinghttps://drive.google.com/drive/folders/16tXOVlxDmNZhKcBppVkOt6O0rzuIFdSE?usp=sharinghttps://drive.google.com/drive/folders/1kg27Ds3zYTfKIEFideN8YO-6csKHLtNm?usp=sharin

Applying supervised machine learning to predict optimal playing positions for rugby players

https://drive.google.com/file/d/1-0IzahwQxlA5IJhjWX3d3wWPzqj5G1dD/view?usp=sharinghttps://drive.google.com/drive/folders/1Kq-9Vr8xmi_vOmvGZfPCjX62tuxq02xS?usp=sharinghttps://drive.google.com/drive/folders/1p2-BLglFh0k-ILOs6gba4TML22L9nKoY?usp=sharin

HT2008-56147 PARAMETRIC CONTROL OF A TWO-PHASE THERMAL MANAGEMENT SYSTEM FOR SPACE APPLICATIONS

ABSTRACT As spacecraft increase in complexity, greater power is required to drive their onboard systems. The resulting generation of waste heat demands efficient thermal control, especially for electrical components emitting heat at high flux densities. Weislogel proposed a passive two-phase heat transport system for space application, driven by constant volume boilers, called the pulse thermal loop (PTL). This paper describes four methods of operating a PTL using real-time pressure data as the control parameter. Preliminary results are presented from an experimental loop using R-134a as the working fluid. Control is exercised through algorithm-based schemes implemented in LabVIEW. Results suggest that stable operation of the loop is best achieved by actuating flow control valves in response to a preset pressure difference between the boilers. Control schemes based on absolute pressure, set pulse frequency, and a combination of absolute and differential pressures are also described. Performance data are presented, and some of the challenges faced during PTL operation are discussed, including start-up and asymmetrical pressurization of the boilers

Comparing PUSH data of rugby players during the off, pre and in season

https://drive.google.com/file/d/1mEHrFVWeWSQeHA_qj5rvaOvAYNSOxxof/view?usp=sharinghttps://drive.google.com/drive/folders/1ApTi9r-z7oje7YFvg_W_hXYml5Hbr6Ei?usp=sharinghttps://drive.google.com/drive/folders/1vOu2PGqpFdKsLUQ7tt1-wEWTX5U5JNTn?usp=sharin

The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care

Background. There is a paucity of data on the pharmacokinetics of fixed-dose combination enteral antituberculosis treatment in critically ill patients. Objectives. To establish the pharmacokinetic profile of a fixed-dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol given according to weight via a nasogastric tube to patients admitted to an intensive care unit (ICU). Methods. We conducted a prospective, observational study on 10 patients (mean age 32 years, 6 male) admitted to an ICU and treated for tuberculosis (TB). Serum concentrations of the drugs were determined at eight predetermined intervals over 24 hours by means of high-performance liquid chromatography. Results. The therapeutic maximum plasma concentration (Cmax) for rifampicin at time to peak concentration was achieved in only 4 patients, whereas 2 did not achieve therapeutic Cmax for isoniazid. No patient reached sub-therapeutic Cmax for pyrazinamide (6 were within and 4 above therapeutic range). Three patients reached sub-therapeutic Cmax for ethambutol, and 6 patients were within and 1 above the therapeutic range. Patients with a sub-therapeutic rifampicin level had a higher mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score (p=0.03) and a lower estimated glomerular filtration rate (GFR) (p=0.03). Conclusions. A fixed-dose combination tablet, crushed and mixed with water, given according to weight via a nasogastric tube to patients with TB admitted to an ICU resulted in sub-therapeutic rifampicin plasma concentrations in the majority of patients, whereas the other drugs had a more favourable pharmacokinetic profile. Patients with a sub-therapeutic rifampicin concentration had a higher APACHE II score and a lower estimated GFR, which may contribute to suboptimal outcomes in critically ill patients. Studies in other settings have reported similar proportions of patients with ‘sub-therapeutic’ rifampicin concentrations

The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care

The original publication is available at http://www.samj.org.zaBackground. There is a paucity of data on the pharmacokinetics of fixed-dose combination enteral antituberculosis treatment in critically ill patients. Objectives. To establish the pharmacokinetic profile of a fixed-dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol given according to weight via a nasogastric tube to patients admitted to an intensive care unit (ICU). Methods. We conducted a prospective, observational study on 10 patients (mean age 32 years, 6 male) admitted to an ICU and treated for tuberculosis (TB). Serum concentrations of the drugs were determined at eight predetermined intervals over 24 hours by means of highperformance liquid chromatography. Results. The therapeutic maximum plasma concentration (Cmax) for rifampicin at time to peak concentration was achieved in only 4 patients, whereas 2 did not achieve therapeutic Cmax for isoniazid. No patient reached sub-therapeutic Cmax for pyrazinamide (6 were within and 4 above therapeutic range). Three patients reached sub-therapeutic Cmax for ethambutol, and 6 patients were within and 1 above the therapeutic range. Patients with a sub-therapeutic rifampicin level had a higher mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score (p=0.03) and a lower estimated glomerular filtration rate (GFR) (p=0.03). Conclusions. A fixed-dose combination tablet, crushed and mixed with water, given according to weight via a nasogastric tube to patients with TB admitted to an ICU resulted in sub-therapeutic rifampicin plasma concentrations in the majority of patients, whereas the other drugs had a more favourable pharmacokinetic profile. Patients with a sub-therapeutic rifampicin concentration had a higher APACHE II score and a lower estimated GFR, which may contribute to suboptimal outcomes in critically ill patients. Studies in other settings have reported similar proportions of patients with ‘sub-therapeutic’ rifampicin concentrations.Publishers' Versio

A capacity framework for strengthening science, education and practice of scaling innovation

This concept note is developed by the CGIAR Initiative for Diversification in East and Southern Africa (Ukama Ustawi). It highlights the significance of strengthening capacity in the science and practice of scaling innovation. The lack of a comprehensive and realistic understanding of innovation and scaling processes, coupled with limited scaling knowledge and capacity across individual, organizational and system levels hinder the effective scaling of innovations. Consequently, many promising initiatives fail to reach their full potential and address systemic issues at scale

Rare Bilateral Nasopalatine Duct Cysts: A Case Report

The nasopalatine duct cyst (NPDC) is the most common of the non-odontogenic cyst of the jaws. This cysts are usually central or unilateral with no prevalence of side occurrence. The NPDC is the most frequent developmental, nonodontogenic cyst of the jaws. This cyst originates from epithelial remnants from the nasopalatine duct. The cells could be activated spontaneously during life, or are eventually stimulated by the irritating action of various agents (infection, etc.). Generally, patients present without clinical signs and symptoms. Therefore, the tentative diagnosis "nasopalatine duct cyst" is often based on a coincidental radiological finding on a routine panoramic view or occlusal radiograph. The definite diagnosis should be based on clinical, radiological and above all histopathologic findings. The therapy of nasopalatine duct cysts consists of an enucleation of the cystic tissue, only in rare cases a marsupialization needs to be performed. This report describes the appearance and treatment of a rare case of bilateral nasopalatine duct cyst